---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-264000"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-06-09T21:04:50+00:00"
generated_at: "2026-06-09T21:06:50.684202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio receives final $4M holdback from AstraZeneca for China ops sale

## Summary
- Received $4.0M from AstraZeneca, satisfying final holdback under February 2025 share purchase agreement.
- Total consideration for sale of China operations was ~$220M ($85M enterprise value + ~$135M net cash).
- Previously received $6.0M holdback plus $0.4M net cash adjustment payment in November 2025.
- With this payment, all owed amounts under the Share Purchase Agreement have been collected.

## SEC filing metadata
- accession: 0001193125-26-264000
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-06-09T21:04:50+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/0001193125-26-264000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/kynb-20260602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-264000
- JSON: https://secwatch.observer/filing/0001193125-26-264000.json
- Plain text: https://secwatch.observer/filing/0001193125-26-264000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.